Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.

Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015 revenue of $1.32-1.34 million, versus the consensus of $1.36 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating